Navigation Links
ProNAi Announces Preclinical Success for PNT2258 Therapeutic -,Curative Events in Xenograft Mice for Difficult-to-Treat,Non-Hodgkin's Lymphoma

LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - ProNAi Therapeutics, Inc., a biopharmaceutical company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi), today announced that its lead oncology therapeutic candidate, PNT2258, has successfully demonstrated preclinical in vivo efficacy in xenograft mice for a number of human cancers - including curative events for difficult-to-treat Burkitt's Lymphoma.

Dr. Richard D. Gill, President and CEO of ProNAi, said, "Team ProNAi is quite pleased with our early preclinical results for PNT2258. Particularly encouraging is the fact that PNT2258 has shown promising single agent efficacy and combination therapy efficacy and drug-dose response for multiple cancer types including both hematological and solid tumors."

He added, "However, a very exciting development was our discovery that PNT2258, in combination with Rituximab, demonstrated curative events in treating Daudi xenografts of human Burkitt's Lymphoma in mice. The antitumor effect was rapid and durable. We had 70% complete remissions in two groups of animals dosed with PNT2258 and Rituximab."

In developing its DNAi(R)-based therapy, ProNAi reports that its successful establishment of in vivo efficacy for formulated PNT2258 included:

-- Single agent efficacy for DLCL2 Xenografts of Human Non-Hodgkin's Lymphoma

-- Combination therapy efficacy with Docetaxel for Human Hormone Refractory Prostate Cancer Xenograft

-- Combination therapy with Rituximab in Daudi Xenografts of Human Burkitt's Lymphoma

ProNAi's preclinical research will proceed in 2007. Planned studies include IND-enabling toxicology and ADME studies. ProNAi will file the IND for PNT2258 later this year.

About DNAi(R)

DNAi(R) (DNA interference) is a novel approach to targeting genomic DNA using sequence-specific therapeutic oligonucleotides, employing single strands of DNA to target
'"/>




Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/20/2014)... LUTHERVILLE, Md. , Aug. 20, 2014 /PRNewswire/ ... today lauded the latest results achieved by the ... known as the National Precursor Log Exchange (NPLEx), ... enforcement officials track down meth offenders and make ... in Kentucky blocked the ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com ... report is available in its catalogue: ... Infection Control (Sterilization, Disinfection, Testing and ... Given the cost ... demand has increased for solutions that ...
(Date:8/20/2014)... Reportbuyer.com has added a new market research report: ... This report analyzes the worldwide markets ... Product Segments: Implantable/Internal Cardiac Defibrillators, and External Defibrillators. The ... Canada , Japan , ... , Middle East & ...
Breaking Medicine Technology:Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6Global Cardiac Defibrillators Industry 2Global Cardiac Defibrillators Industry 3Global Cardiac Defibrillators Industry 4Global Cardiac Defibrillators Industry 5Global Cardiac Defibrillators Industry 6Global Cardiac Defibrillators Industry 7Global Cardiac Defibrillators Industry 8Global Cardiac Defibrillators Industry 9Global Cardiac Defibrillators Industry 10Global Cardiac Defibrillators Industry 11Global Cardiac Defibrillators Industry 12Global Cardiac Defibrillators Industry 13Global Cardiac Defibrillators Industry 14Global Cardiac Defibrillators Industry 15Global Cardiac Defibrillators Industry 16Global Cardiac Defibrillators Industry 17Global Cardiac Defibrillators Industry 18Global Cardiac Defibrillators Industry 19Global Cardiac Defibrillators Industry 20
... SILVER SPRING, Md., April 15, 2011 The U.S. ... given alone or in combination with methotrexate, for ... (SJIA) in children ages 2 years and older. ... SJIA, or Still,s disease, is a rare, potentially ...
... Inc., owner and operator of both Reptrax and VendorClear, ... leading vendor compliance solution. With the acquisition of Status ... industry,s credentialing efforts onto one standardized platform. Status Blue, ... care and grounded credentialing principles that are shared by ...
Cached Medicine Technology:FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis 2FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis 3IntelliCentrics, Inc. Acquires Hospital Vendor Credentialing Solution Status Blue, LLC 2IntelliCentrics, Inc. Acquires Hospital Vendor Credentialing Solution Status Blue, LLC 3
(Date:8/20/2014)... 2014 Ticket Down is a reliable ... NYC. In just a week, the U.S. Open Tennis Championship ... The event was originally founded in 1881 and features grass courts ... forced to withdrawal from the event because of a wrist injury. ... will return to New York City with hopes of winning her ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. ... dramatically during the past two decades, plummeting 57 percent and ... An estimated 4 million fewer births occurred among teenagers ... the U.S. Centers for Disease Control and Prevention. That ... report," said Bill Albert, chief program officer of The National ...
(Date:8/20/2014)... examined patient and tumor characteristics for melanomas with ... growth) in an effort to increase earlier detection ... , Author: Sarah Shen, M.B.B.S., B.Med.Sci., of ... Background: The tumor characteristic known as mitotic ... with prognosis and survival in melanoma patients. However, ...
(Date:8/20/2014)... discovered that the immune system is defective in people suffering ... sufferers have ongoing issues with pain. , The research ... also help to explain why some painkillers may not offer ... up to 10% of the community. There are different ... pain, which often has the greatest impact on sufferers, quality ...
(Date:8/20/2014)... now, Free content, The time to deploy Ebola ... published early online today in Annals of ... of Public Health write that the relentless epidemiologic trajectory ... a public health crisis that shows no signs of ... developed in the last decade, yet the sporadic nature ...
Breaking Medicine News(10 mins):Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 2Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 3Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 4Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 5Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 2Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 3Health News:Patient, tumor characteristics for high-mitotic rate melanoma 2Health News:Pain treatments less effective for those with irritable bowel 2Health News:News from Annals of Internal Medicine 2
... The following fact sheet was released today by ... We Fail Partnership (AARP, Business Roundtable, National Federation of ... Divided We Fail, we urge you to act promptly ... Program (SCHIP). Our nation has a duty to give ...
... journal report:Study highlights:-- Cholesterol-lowering drug adherence drops with ... of going for 90 straight days without medication ... all co-payment group and twice as high in ... to the exempt group (received prescriptions without a ...
... Benzoyl Peroxide Wash to Utilize MICROSPONGE(R) Delivery SystemCARLSBAD, ... the launch of NeoBenz Micro Wash, ... with the MICROSPONGE (R) delivery system, for ... NeoBenz Micro Wash contains 7% benzoyl ...
... 29 Years of Experience with Complex Rehab MarketHOUSTON, Jan. ... almost 30 years of experience, has joined Alliance ... fastest growing accredited complex rehab companies. Kieschnik is an ... Technology Supplier (CRTS) in Houston, Texas, for ASM ( ...
... Association rapid access journal reportStudy highlights:, , ... determine the odds of having cardiovascular disease within 10 years may ... Most adults 50 years and younger have a low ... for heart disease. , Researchers ...
... urban areas , , WEDNESDAY, Jan. 14 (HealthDay News) -- ... are making a comeback in some urban areas, a new ... where infestations have grown in recent years, appear to have ... pyrethroid toxins, such as deltamethrin, commonly used against them, according ...
Cached Medicine News:Health News:Health Care For 11 Million Children 2Health News:Health Care For 11 Million Children 3Health News:Health Care For 11 Million Children 4Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 2Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 3Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 4Health News:SkinMedica(R) Launches NeoBenz(R) Micro Wash for Acne 2Health News:SkinMedica(R) Launches NeoBenz(R) Micro Wash for Acne 3Health News:Veteran Rehab Specialist, Anne Kieschnik, Joins Fast-Growing Alliance Seating & Mobility In Texas 2Health News:Veteran Rehab Specialist, Anne Kieschnik, Joins Fast-Growing Alliance Seating & Mobility In Texas 3Health News:Half of Adults 50 and Younger With Low 10-Year Risk of CVD Have High Lifetime Risk 2Health News:Half of Adults 50 and Younger With Low 10-Year Risk of CVD Have High Lifetime Risk 3Health News:Bed Bugs, Nearly Eradicated, Make a Comeback 2
For primary and revision cases...
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Standard Erlanger hip stem....
Cemented foundation 460 series....
Medicine Products: